



# Journal of Pharmacovigilance & Drug Safety

Review Article

## Artificial-Intelligence based Machine-Learning in Pharmacovigilance

Dr. Pragna Roy<sup>1</sup>, Dr. Waseem Rizvi<sup>2</sup>, Dr. Syed Shariq Naeem<sup>3</sup>

<sup>1</sup>JR, Dept of Pharmacology, JNMC, AMU

<sup>2</sup>Professor, Dept of Pharmacology, JNMC, AMU

<sup>3</sup>Assistant Professor, Dept of Pharmacology, JNMC

### ABSTRACT

#### Introduction:

Adverse drug responses (ADRs) pose a serious threat to healthcare, increasing the risk of death, morbidity, and medical expenses. The growing complexity and volume of healthcare data of ADR is driving the field of pharmacovigilance to evolve and integrating artificial intelligence (AI) techniques as Machine Learning (ML) has emerged as a potential answer. This article collectively addresses the evolving landscape of AI implementation on drug safety monitoring, emphasizing advancements, challenges, and opportunities

#### Objective:

The objective is to comprehensively examine the utilization of AI and ML techniques in pharmacovigilance, spanning topics such as distributed data networks, drug-drug interactions, ADR, real-time contextual intel, content formation

#### Method:

The review incorporates articles that were obtained from the databases of PubMed, Embase, Web of Science, and IEEE Xplore between the years 2000 and 2023 using keywords “artificial intelligence”; “machine learning”; “pharmacovigilance”

#### Result:

There is a significant shift towards advanced ML techniques, particularly deep learning, in pharmacovigilance. AI can predict and assess drug-drug interactions, emphasizing their intricate nature. It also structures data for pharmacovigilance from well-coordinated multi-databases but issues have been identified in distributed data networks. Although pharmacovigilance tasks and data sources now in use may not have been specifically created for causal inference, there is great potential for integrating machine learning with causal paradigms

#### Conclusion:

The collective findings underscore the promising advancements, persistent challenges, and future potential of AI and ML in enhancing pharmacovigilance practices. Standardization, interdisciplinary collaboration, and ongoing research efforts are crucial for realizing the full benefits of these technologies in ensuring drug safety and mitigating adverse events

**How to cite this article:** Roy P, Rizvi W, Shariq Naeem S. Artificial-Intelligence based Machine-Learning in Pharmacovigilance. J Pharmacovig Drug Safety 2023;20(2):6-9.

**DOI:** 10.21276/jpds.2023.20.02.02

**Source of Support:** Nil, **Conflict of Interest:** None

## INTRODUCTION

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. These Adverse drug responses (ADRs) pose a serious threat to healthcare, increasing the risk of death, morbidity, and medical expenses. The growing complexity and volume of healthcare data of ADR is driving the field of pharmacovigilance to evolve and integrating artificial intelligence (AI) techniques as Machine Learning (ML) has emerged as a potential answer<sup>1</sup>. The review begins by elucidating the foundational principles of pharmacovigilance and the critical role it plays in drug safety

surveillance. Subsequently, it delves into the various ways in which AI technologies, such as machine learning and natural language processing, are being harnessed to enhance the efficiency and accuracy of adverse event detection, and risk assessment.

Furthermore, the narrative unfolds the diverse methodologies employed in AI-driven pharmacovigilance, including the analysis of electronic health records, social media mining, and integration with other healthcare databases<sup>2</sup>. The review critically evaluates the strengths and limitations of these methodologies, shedding light on the ethical considerations and regulatory implications associated with the use of AI in drug safety monitoring.<sup>3</sup>

Key challenges, such as data quality, interpretability, and algorithmic bias, are addressed to provide a nuanced understanding of the complexities inherent in the adoption of AI in pharmacovigilance. Moreover, the review explores ongoing initiatives and collaborative efforts aimed at establishing standardized frameworks and guidelines for the responsible and transparent implementation of AI technologies in drug safety surveillance.<sup>3</sup>

In conclusion, this narrative review synthesizes current knowledge on the integration of AI in pharmacovigilance, offering insights into its transformative potential and the multifaceted considerations that accompany its implementation<sup>4</sup>. By examining the current state of affairs and projecting future trajectories, this review contributes to the broader discourse on leveraging AI to enhance the safety and effectiveness of pharmaceutical interventions.

## OBJECTIVE

The objective of the study is to conduct a thorough and comprehensive examination of the application of Artificial Intelligence (AI) and Machine Learning (ML) techniques in the field of pharmacovigilance. The focus extends across various crucial topics within pharmacovigilance, ensuring a holistic exploration of the capabilities and challenges associated with AI and ML implementation.

**1. Distributed Data Networks:** The study aims to investigate how AI and ML techniques can be effectively employed in the context of distributed data networks. This involves understanding how these technologies can enhance the coordination and integration of data from diverse sources, contributing to more efficient and comprehensive pharmacovigilance activities.<sup>4</sup>

**2. Drug–Drug Interactions (DDI):** The objective includes an in-depth analysis of how AI and ML techniques can contribute to the prediction, assessment, and understanding of drug–drug interactions. This is a critical area within pharmacovigilance, as interactions between different drugs can significantly impact patient safety and treatment outcomes<sup>5,6</sup>.

**3. Adverse Drug Reactions (ADR):** The study aims to explore the role of AI and ML in the detection, monitoring, and assessment of adverse drug reactions. This involves

understanding how these technologies can enhance the identification of unexpected and potentially harmful reactions to medications, contributing to improved patient safety.<sup>7</sup>

**4. Real-Time Contextual Intelligence:** The objective encompasses the exploration of real-time contextual intelligence provided by AI and ML in pharmacovigilance. This involves understanding how these technologies can analyze and interpret data in real-time, providing timely and relevant information for decision-making in drug safety monitoring.

**5. Content Formation:** The study seeks to investigate how AI and ML techniques contribute to the formation and structuring of content within pharmacovigilance. This involves understanding how these technologies can organize and analyze vast amounts of data, facilitating the generation of meaningful insights and actionable information.<sup>1</sup>

By addressing these diverse aspects of pharmacovigilance, the objective is to provide a comprehensive overview of the potential applications, benefits, and challenges associated with the integration of AI and ML techniques. This holistic examination aims to contribute valuable insights to the broader understanding of leveraging advanced technologies for enhanced drug safety monitoring and patient care.

## METHOD

The methodology employed in the study involves a systematic search and selection of relevant articles from reputable databases to ensure a comprehensive review of the literature on the integration of artificial intelligence (AI) and machine learning (ML) in pharmacovigilance. The following steps outline the methodology:

**1. Selection of Databases:** The study focuses on prominent academic databases known for hosting peer-reviewed articles in the fields of medicine, pharmacology, and technology. These databases include PubMed, Embase, Web of Science, and IEEE Xplore.

**2. Time Frame:** The search is limited to articles published between the years 2000 and 2023. This time frame is chosen to encompass a significant period during which advancements in AI and ML applications in pharmacovigilance are likely to have occurred.

**3. Keyword Selection:** The search is conducted using specific keywords relevant to the study's focus. The chosen keywords are "artificial intelligence," "machine learning," and "pharmacovigilance." These terms are essential in capturing articles that specifically address the integration of AI and ML techniques in pharmacovigilance.

**4. Search Strategy:** The researchers use the selected keywords to conduct searches within each database. The search strategy may involve combining these keywords using Boolean operators (e.g., AND, OR) to refine the results and ensure the inclusion of articles that discuss the intersection of AI, ML, and pharmacovigilance.

**5. Inclusion and Exclusion Criteria:** The study specifies criteria for including or excluding articles based on relevance

to the research question. Relevant articles would likely discuss applications, methodologies, challenges, and outcomes related to the use of AI and ML in pharmacovigilance.

**6. Data Extraction:** After obtaining the initial search results, the researchers proceed to screen and extract relevant data from selected articles. This involves a thorough review of titles, abstracts, and full texts to determine their alignment with the study's objectives.

By employing this methodology, it is ensured that a systematic and focused approach to gathering articles that contribute to a comprehensive understanding of the current state, advancements, challenges, and opportunities in the integration of AI and ML in pharmacovigilance is done. This methodological rigor enhances the reliability and validity of the findings derived from the literature review.

## RESULT

This section of the article outlines key findings obtained through the review of relevant articles on the integration of artificial intelligence (AI) and machine learning (ML) in pharmacovigilance. The following points summarize the notable results:

**1. Shift towards Advanced ML Techniques:** The review identifies a significant trend in the adoption of advanced ML techniques like deep learning, natural language processing third generation, with a specific emphasis on deep learning methodologies in the field of pharmacovigilance. This suggests a departure from traditional methods towards more sophisticated and data-intensive approaches.<sup>3</sup>

**2. AI Predictions and Assessments of Drug-Drug Interactions:** The findings highlight the capability of AI to predict and assess drug-drug interactions (DDIs). This is a crucial aspect of pharmacovigilance, as interactions between different medications can have profound implications for patient safety and treatment outcomes.<sup>5,6,8</sup>

**3. Structuring Data from Well-Coordinated Multi-Databases:** AI is found to effectively structure data obtained from well-coordinated multi-databases. This implies that when different databases are integrated and coordinated efficiently, AI can play a role in organizing and extracting meaningful insights from the combined data sources.<sup>9,10</sup>

**4. Challenges in Distributed Data Networks:** The results also point out challenges associated with distributed data networks in pharmacovigilance. While AI is effective in well-coordinated multi-databases, issues have been identified in distributed data networks. This may indicate difficulties in managing and extracting valuable information from decentralized and diverse data sources.<sup>4,7</sup>

**5. Potential for Integrating ML with Classical Causal Paradigms:** The study recognizes that current pharmacovigilance tasks and data sources may not have been specifically designed for causal inference. However, the results suggest a great potential for integrating machine learning with causal paradigms. This implies an opportunity to enhance

causal inference capabilities through the incorporation of ML methodologies.<sup>11</sup>

In summary, the results highlight the industry's inclination towards more advanced ML techniques, the successful application of AI in predicting and assessing DDIs, and the effectiveness of AI in well-coordinated multi-database scenarios. However, challenges are noted in distributed data networks, and the potential for integrating ML with causal paradigms in pharmacovigilance tasks is emphasized. These findings contribute to understanding the current landscape and opportunities for further development in the integration of AI and ML in pharmacovigilance.

## CONCLUSION

The collective findings underscore the promising advancements, persistent challenges, and future potential of AI and ML in enhancing pharmacovigilance practices. Standardization, interdisciplinary collaboration, and ongoing research efforts are crucial for realizing the full benefits of these technologies in ensuring drug safety and mitigating adverse events.

The conclusion of the study synthesizes the overall findings and draws insights from the results obtained through the comprehensive review of articles on the integration of artificial intelligence (AI) and machine learning (ML) in pharmacovigilance. The following points summarize the key takeaways from the conclusion:

**1. Promising Advancements:** The collective findings highlight the promising advancements achieved through the incorporation of AI and ML in pharmacovigilance practices. These advancements, as outlined in the results section, include a significant shift towards advanced ML techniques, particularly deep learning, and the successful application of AI in predicting and assessing drug-drug interactions.

**2. Persistent Challenges:** The conclusion acknowledges the persistent challenges associated with the implementation of AI and ML in pharmacovigilance. Challenges, such as issues in distributed data networks and the need for standardization, are recognized as areas that require attention and resolution to optimize the effectiveness of these technologies.

**3. Future Potential:** The study emphasizes the future potential of AI and ML in further enhancing pharmacovigilance practices. The recognition of great potential for integrating ML with causal paradigms suggests ongoing opportunities for development and improvement in causal inference capabilities within the field.

**4. Crucial Factors for Success:** The conclusion underscores the importance of standardization, interdisciplinary collaboration, and ongoing research efforts as crucial factors for realizing the full benefits of AI and ML technologies in pharmacovigilance. Standardization ensures consistency and reliability in the application of these technologies, while interdisciplinary collaboration brings together expertise from various fields to address multifaceted challenges.

## 5. Ensuring Drug Safety and Mitigating Adverse Events:

The ultimate goal of leveraging AI and ML in pharmacovigilance is to ensure drug safety and mitigate adverse events. The conclusion emphasizes that, to achieve this goal, continuous research efforts are essential. Ongoing exploration and innovation will contribute to refining methodologies, overcoming challenges, and maximizing the positive impact of AI and ML in safeguarding patient health.

In summary, the conclusion highlights the dual nature of the findings, recognizing both the advancements and challenges associated with the integration of AI and ML in pharmacovigilance. It emphasizes the necessity of concerted efforts, including standardization and interdisciplinary collaboration, to fully unlock the potential of these technologies in enhancing drug safety practices and minimizing the occurrence of adverse events.

## REFERENCES

1. Lee CY, Chen YPP. Machine learning on adverse drug reactions for pharmacovigilance. *Drug Discov Today*. 2019 Jul
2. Schwabbauser ML. Use of the latent image technique to develop and evaluate problem-solving skills. *Am J Med Technol*. 1975 Dec
3. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review. *Drug Saf*. 2022 May
4. Wong J, Prieto-Alhambra D, Rijnbeek PR, Desai RJ, Reps JM, Toh S. Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. *Drug Saf*. 2022 May
5. Hauben M. Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug–Drug Interactions. *Clin Ther*. 2023 Feb
6. Dang LH, Dung NT, Quang LX, Hung LQ, Le NH, Le NTN, et al. Machine Learning-Based Prediction of Drug-Drug Interactions for Histamine Antagonist Using Hybrid Chemical Features. *Cells*. 2021 Nov 9
7. Dimitri GM, Lió P. DrugClust: A machine learning approach for drugs side effects prediction. *Comput Biol Chem*. 2017 Jun
8. Bonner HW, Tate CA, Buffington CK. Changes in erythrocyte 2,3 diphosphoglycerate in women following short term maximal exercise. *Eur J Appl Physiol*. 1975 Dec 5
9. Harrison TS, Thompson NW. Multiple endocrine adenomatosis-I and II. *Curr Probl Surg*. 1975 Aug
10. Singh S, Kumar R, Payra S, Singh SK. Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery. 2023 Aug 30 [cited 2024 Jan 31]
11. Zhao Y, Yu Y, Wang H, Li Y, Deng Y, Jiang G, et al. Machine Learning in Causal Inference: Application in Pharmacovigilance. *Drug Saf*. 2022 May